Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.05 0.95% 5.30 5.20 5.40 5.35 5.25 5.25 297,195 16:21:13
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -3.2 -1.8 - 15

Evgen Pharma PLC Appointment of Chief Medical Officer

26/04/2021 7:00am

UK Regulatory (RNS & others)


Evgen Pharma (LSE:EVG)
Historical Stock Chart


From Apr 2021 to Jul 2021

Click Here for more Evgen Pharma Charts.

TIDMEVG

RNS Number : 4916W

Evgen Pharma PLC

26 April 2021

Evgen Pharma Plc

("Evgen" or "the Company")

Appointment of Chief Medical Officer

Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome, announces that Glen Clack, MD, FFPM will be joining the Company as Chief Medical Officer effective from 1 May 2021.

Dr Clack has over 30 years' experience in oncology and translational medicine, and held various roles within AstraZeneca for almost 20 years. Dr Clack has specialised in early phase oncology clinical development with an emphasis on a number of important cancers and has a wealth of experience in conducting and managing clinical trials. He has successfully p rovided strategic and operational leadership from Phase I through to regulatory submissions and commercialisation. He has been a lead member of study, clinical development and project teams on multiple trials.

Glen is an Honorary Professor of Translational Medicine at the University of Sheffield and an MSc Module Tutor and Honorary Lecturer in Translational Science at the University of Manchester. He has an MB BS from the Royal Free Hospital School of Medicine in London, is a Fellow of the Faculty of Pharmaceutical Medicine at the University of Wales and holds an MD from the University of Sheffield.

Dr Huw Jones CEO of Evgen commented: "We are delighted to have someone of Glen's experience and knowledge join our team. As we progress further with our clinical programmes, Glen's depth of understanding in the fields where we are active will be invaluable. Glen will also be a key member of the team involved in leveraging our relationships with our many partners. His unique skillset has seen him take responsibility for a number of large, complex projects and he has published over 50 academic papers on various cancers."

Enquiries:

 
 Evgen Pharma plc www.evgen.com                                           via Walbrook 
 Barry Clare, Chairman 
 Richard Moulson, CFO 
 
 finnCap www.finncap.com                                           +44 (0)20 7220 0500 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane (ECM) 
 
 Walbrook PR                              +44 (0)20 7933 87870 or evgen@walbrookpr.com 
                                                     +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                    741 001 
 
 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.

The Company commenced operations in January 2008 and has its headquarters at Alderley Park, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

For research on the Company, please visit: http://evgen.com/investors/analyst-coverage/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCDKNBDQBKDOQB

(END) Dow Jones Newswires

April 26, 2021 02:00 ET (06:00 GMT)

1 Year Evgen Pharma Chart

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

1 Month Evgen Pharma Chart
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210726 02:52:40